Medicare Enrolled

Dr. Veena Chandrakar, M.D.

Medical Oncology · Cypress, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Speaking/Promotional
27700 HIGHWAY 290 STE 400, Cypress, TX 77433
8323773260
In practice since 2005 (20 years)
NPI: 1295738342 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Chandrakar from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Chandrakar? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Chandrakar

Dr. Veena Chandrakar is a medical oncology in Cypress, TX, with 20 years in practice. Based on federal Medicare data, Dr. Chandrakar performed 49,819 Medicare services across 904 unique beneficiaries.

Between the years covered by Open Payments, Dr. Chandrakar received a total of $93,857 from 83 pharmaceutical and/or device companies across 756 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Chandrakar is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 20 years in practice▲ Top 20% volume in TX$ $93,857 industry payments

Medicare Practice Summary

Medicare Utilization ↗
49,819
Medicare services
Top 20% in TX for medical oncology
904
Unique beneficiaries
$5
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~2,491 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

ProcedureVolumeAvg. paidAvg. submitted
Iron infusion (Feraheme)43,860$0$2
Denosumab injection (Prolia/Xgeva)2,640$19$94
Dexamethasone injection (steroid)1,353$0$1
Office visit, established patient (30-39 min)566$93$395
Office visit, established patient (20-29 min)254$68$280
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less233$23$91
Complete blood count (CBC) with differential190$8$24
Administration of chemotherapy into vein, 1 hour or less149$102$416
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less138$49$204
Drug injection, under skin or into muscle121$11$51
New patient office visit (45-59 min)68$119$518
Blood draw (venipuncture)58$8$11
Nuclear medicine study from skull base to mid-thigh with ct scan57$1,183$5,308
Injection of additional new drug or substance into vein57$12$51
Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries55$101$377
New patient office visit (30-44 min)20$88$350
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
88.8% high complexity
8.8% medium
2.4% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$93,857
Total received (2018-2024)
Avg $13,408/year across 7 years
Top 15% in TX for medical oncology
83
Companies
756
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$69,550 (74.1%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$13,870 (14.8%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$10,437 (11.1%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$12,405
2023
$22,338
2022
$20,976
2021
$21,836
2020
$9,693
2019
$4,737
2018
$1,872

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
SOBI, INC
$21,223
Sobi, Inc
$16,960
Dova Pharmaceuticals
$15,419
Sirtex Medical Inc
$14,686
Regeneron Pharmaceuticals, Inc.
$3,826
Celgene Corporation
$3,140
GENZYME CORPORATION
$2,805
Regeneron Healthcare Solutions, Inc.
$1,803
Amgen Inc.
$1,580
E.R. Squibb & Sons, L.L.C.
$1,161
Novartis Pharmaceuticals Corporation
$716
AstraZeneca Pharmaceuticals LP
$694
CTI BioPharma Corp.
$667
Lilly USA, LLC
$626
PFIZER INC.
$600
Merck Sharp & Dohme Corporation
$585
Janssen Biotech, Inc.
$543
Astellas Pharma US Inc
$535
Myriad Genetic Laboratories, Inc.
$402
Incyte Corporation
$358
Boehringer Ingelheim Pharmaceuticals, Inc.
$341
Merck Sharp & Dohme LLC
$334
Janssen Pharmaceuticals, Inc
$333
GlaxoSmithKline, LLC.
$285
PharmaEssentia USA Corporation
$275
BeiGene USA, Inc.
$208
AMAG Pharmaceuticals, Inc.
$203
Daiichi Sankyo Inc.
$201
Rigel Pharmaceuticals, Inc.
$195
Eisai Inc.
$191
Tempus AI, Inc
$174
Seagen Inc.
$144
Bayer HealthCare Pharmaceuticals Inc.
$129
Genentech USA, Inc.
$123
Gilead Sciences, Inc.
$113
SpringWorks Therapeutics, Inc.
$109
Apellis Pharmaceuticals, Inc.
$108
Alexion Pharmaceuticals, Inc.
$103
Pharmacyclics LLC, An AbbVie Company
$96
Teva Pharmaceuticals USA, Inc.
$89
PUMA BIOTECHNOLOGY, INC.
$88
Kyowa Kirin, Inc.
$83
Puma Biotechnology, Inc.
$81
EMD Serono, Inc.
$76
Taiho Oncology, Inc.
$73
Ipsen Biopharmaceuticals, Inc
$70
Blueprint Medicines Corporation
$66
Mylan Institutional Inc.
$64
AVEO Pharmaceuticals, Inc.
$59
Takeda Pharmaceuticals U.S.A., Inc.
$56
MorphoSys, US Inc.
$55
Exelixis Inc.
$55
AbbVie Inc.
$51
Foundation Medicine, Inc.
$50
Pharmacyclics LLC, an AbbVie Company
$49
Clovis Oncology, Inc.
$49
TESARO, Inc.
$49
Myovant Sciences Inc.
$49
Karyopharm Therapeutics Inc.
$48
SANOFI-AVENTIS U.S. LLC
$46
TAIHO ONCOLOGY, INC.
$42
Tactile Systems Technology Inc
$40
Pharmacosmos Therapeutics Inc.
$36
Alnylam Pharmaceuticals Inc.
$33
SANOFI US SERVICES INC.
$32
ABBVIE INC.
$31
Immunocore Limited
$29
Spectrum Pharmaceuticals Inc.
$29
EISAI INC.
$27
Dendreon Pharmaceuticals LLC
$25
Fennec Pharmaceuticals, Inc.
$24
TerSera Therapeutics LLC
$24
JAZZ PHARMACEUTICALS INC.
$23
Deciphera Pharmaceuticals Inc.
$21
G1 Therapeutics, Inc.
$20
Servier Pharmaceuticals LLC
$19
Secura Bio, Inc.
$18
Chiesi USA, Inc.
$16
Lexicon Pharmaceuticals, Inc.
$15
MEDIVATION FIELD SOLUTIONS LLC
$14
Global Blood Therapeutics, Inc.
$14
Octapharma USA, Inc.
$13
Seattle Genetics, Inc.
$11
Top 3 companies account for 57.1% of total payments
Associated products mentioned in payments ›
ABECMA · ADCETRIS · ALIMTA · AYVAKIT · BAVENCIO · BENDEKA · BESREMI · BLENREP · BOSULIF · BRUKINSA · Bavencio · Blincyto · CABOMETYX · CALQUENCE · CHANTIX · COSELA · CYRAMZA · Cabometyx · Columvi · DARZALEX · DOPTELET · Doptelet · ELIQUIS · ELITEK · EMPLICITI · ENHERTU · ENJAYMO · EPKINLY · ERBITUX · ERLEADA · EVENITY · Empaveli · Enhertu · Erleada · FARYDAK · FERAHEME · FERRIPROX · FLEXITOUCH · FOTIVDA · FOUNDATIONONE · Fabhalta · Flexitouch Plus · Fulphila · GILOTRIF · GIVLAARI · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · INQOVI · INVOKANA · JADENU · JAKAFI · JEVTANA · KANJINTI · KEYTRUDA · KIMMTRAK · KISQALI · Kyprolis · LIBTAYO · LONSURF · LUMAKRAS · LYNPARZA · Lenvima · Lonsurf · Lunsumio · MEKINIST · MONJUVI · MONOFERRIC · MVASI · MYLOTARG · MYRISK · NERLYNX · NINLARO · Neulasta · Nexavar · Nplate · Nubeqa · OGSIVEO · OJJAARA · OPDIVO · OPDUALAG · ORGOVYX · OXBRYTA · Ogivri · Onivyde · PADCEV · POTELIGEO · PRECISETUMOR · PROMACTA · PROVENGE · Padcev · Pedmark · Pomalyst · Poteligeo · Prolia · QINLOCK · REBLOZYL · ROLVEDON · RYBREVANT · RYDAPT · Revlimid · Rezlidhia · Rubraca · SANCUSO · SARCLISA · SCEMBLIX · SIR-Spheres Microspheres · SOLIRIS · SOMATULINE DEPOT · SUTENT · TAGRISSO · TASIGNA · TECENTRIQ · TECVAYLI · TIBSOVO · TUKYSA · Tavalisse · Tecentriq · Trodelvy · Truxima · ULTOMIRIS · VENCLEXTA · VERZENIO · VONJO · Vectibix · Vonjo · Vyloy · WILATE · XALKORI · XARELTO · XGEVA · XOSPATA · XPOVIO · XT CDX · XTANDI · Xermelo · Xofigo · Xtandi · ZEJULA · ZEPZELCA · Zoladex · myRisk
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (74%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in medical oncology and does not inherently indicate bias, but patients may wish to be aware.

Equivalent to $188 per 100 Medicare services performed
Looking for a medical oncology in Cypress?
Compare medical oncologys in the Cypress area by procedure volume, costs, and industry payment transparency.
Browse medical oncologys nearby

Geographic Context

Medical Oncologys within 10 mi
18
Per 100K population
0.4
County median income
$73,104
Nearest hospital
LONE STAR BEHAVIORAL HEALTH CYPRESS
5.7 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment PECOSMonthly updates
Practice Data Medicare Util.Annual (CY lag)
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Chandrakar is a mixed practice specialist, with above-average Medicare volume (top 20% in TX), and high industry engagement (speaking/promotional, top 15%), with 20 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Chandrakar experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Chandrakar performed 43,860 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Chandrakar receive payments from pharmaceutical companies?
Yes. Dr. Chandrakar received a total of $93,857 from 83 companies across 756 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Chandrakar's costs compare to other medical oncologys in Cypress?
Dr. Chandrakar's average Medicare payment per service is $5. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Chandrakar) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →